Iron homeostasis and toxicity in retinal degeneration

Progress in Retinal and Eye Research

Volumn 26, Issue 6, 2007, Pages 649-673

  He, Xining ^a   Hahn, Paul ^a   Iacovelli, Jared ^a   Wong, Robert ^a   King, Chih ^a   Bhisitkul, Robert ^b   Massaro Giordano, Mina ^a   Dunaief, Joshua L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age related macular degeneration; Ceruloplasmin; Chelator; Ferritin; Ferroportin; Hephaestin.; Iron; Oxidative stress; Retina

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CERULOPLASMIN; FERRITIN; FERROPORTIN 1; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; HEPCIDIN; HLA ANTIGEN CLASS 1; HYDROXYL GROUP; IRON; N METHYL DEXTRO ASPARTIC ACID; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN; TRANSFERRIN RECEPTOR; ZINC;

CELL CULTURE; CORNEA; EYE EXAMINATION; FRIEDREICH ATAXIA; GENE MUTATION; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; IRON BALANCE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; IRON TRANSPORT; LENS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RETINA CELL; RETINA DEGENERATION; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIDEROSIS; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL TRANSPORT; EPITHELIAL CELLS; HOMEOSTASIS; HUMANS; IRON; LENS, CRYSTALLINE; OXIDATIVE STRESS; RETINA; RETINAL DEGENERATION;

EID: 35348944706     PISSN: 13509462     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2007.07.004     Document Type: Review

References (148)

1. Abboud S., and Haile D.J. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J. Biol. Chem. 275 (2000) 19906-19912
2. Aisen P., Enns C., and Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int. J. Biochem. Cell Biol. 33 (2001) 940-959
3. Anderson L.J., Wonke B., Prescott E., Holden S., Walker J.M., and Pennell D.J. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360 (2002) 516-520
4. Aouad F., Florence A., Zhang Y., Collins F., Henry C., Ward R.J., and Crichton R. Evaluation of new iron chelators and their therapeutic potential. Inorg. Chim. Acta 339 (2002) 470-480
5. AREDS. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 119 (2001) 1417-1436
6. Baker E., and Morgan E.H. Iron transport. In: Brock J., Halliday J.H., Pippard M.H., and Powell L.W. (Eds). Iron Metabolism in Health and Disease (1994), W.B. Saunders, Philadelphia 63-95
7. Beatty S., Koh H., Phil M., Henson D., and Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 45 (2000) 115-134
8. Beinert H., and Kiley P. Redox control of gene expression involving iron-sulfur proteins. Change of oxidation-state or assembly/disassembly of Fe-S clusters?. FEBS Lett. 382 (1996) 218-219 (discussion 220-211)
9. Bergeron R.J., Wiegand J., and Brittenham G.M. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 99 (2002) 3019-3026
10. Boddaert N., Le Quan Sang K.H., Rotig A., Leroy-Willig A., Gallet S., Brunelle F., Sidi D., Thalabard J.C., Munnich A., and Cabantchik Z.I. Selective iron chelation in Friedreich ataxia. Biological and clinical implications. Blood (2007)
11. Brill P.W., Winchester P., Giardina P.J., and Cunningham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. Am. J. Roentgenol. (AJR) 156 (1991) 561-565
12. Burdo J.R., Martin J., Menzies S.L., Dolan K.G., Romano M.A., Fletcher R.J., Garrick M.D., Garrick L.M., and Connor J.R. Cellular distribution of iron in the brain of the Belgrade rat. Neuroscience 93 (1999) 1189-1196
13. Burdo J.R., Menzies S.L., Simpson I.A., Garrick L.M., Garrick M.D., Dolan K.G., Haile D.J., Beard J.L., and Connor J.R. Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J. Neurosci. Res. 66 (2001) 1198-1207
14. Burdo J.R., Antonetti D.A., Wolpert E.B., and Connor J.R. Mechanisms and regulation of transferrin and iron transport in a model blood-brain barrier system. Neuroscience 121 (2003) 883-890
15. Campochiaro P.A. Gene therapy for ocular neovascularization. Curr. Gene Ther. 7 (2007) 25-33
16. Cazzola M., Invernizzi R., Bergamaschi G., Levi S., Corsi B., Travaglino E., Rolandi V., Biasiotto G., Drysdale J., and Arosio P. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 101 (2003) 1996-2000
17. Ceci A., Baiardi P., Felisi M., Cappellini M.D., Carnelli V., De Sanctis V., Galanello R., Maggio A., Masera G., Piga A., Schettini F., Stefano I., and Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br. J. Haematol. 118 (2002) 330-336
18. Cheah J.H., Kim S.F., Hester L.D., Clancy K.W., Patterson III S.E., Papadopoulos V., and Snyder S.H. NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 51 (2006) 431-440
19. Chen L., Dentchev T., Wong R., Hahn P., Wen R., Bennett J., and Dunaief J.L. Increased expression of ceruloplasmin in the retina following photic injury. Mol. Vis. 9 (2003) 151-158
20. Chowers I., Wong R., Dentchev T., Farkas R.H., Iacovelli J., Gunatilaka T.L., Medeiros N.E., Presley J.B., Campochiaro P.A., Curcio C.A., Dunaief J.L., and Zack D.J. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2135-2140
21. Cibis P.A., Yamashita T., and Rodriguez F. Clinical aspects of ocular siderosis and hemosiderosis. AMA Arch. Ophthalmol. 62 (1959) 180-187
22. Cohen A.R., Galanello R., Piga A., De Sanctis V., and Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102 (2003) 1583-1587
23. Cozzi A., Corsi B., Levi S., Santambrogio P., Albertini A., and Arosio P. Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ferroxidase activity. J. Biol. Chem. 275 (2000) 25122-25129
24. Dautry-Varsat A., Ciechanover A., and Lodish H.F. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA 80 (1983) 2258-2262
25. De Domenico I., Ward D.M., Nemeth E., Vaughn M.B., Musci G., Ganz T., and Kaplan J. The molecular basis of ferroportin-linked hemochromatosis. Proc. Natl. Acad. Sci. USA 102 (2005) 8955-8960
26. De Virgiliis S., Congia M., Frau F., Argiolu F., Diana G., Cucca F., Varsi A., Sanna G., Podda G., Fodde M., et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J. Pediatr. 113 (1988) 661-669
27. Declercq S.S., Meredith P.C., and Rosenthal A.R. Experimental siderosis in the rabbit: correlation between electroretinography and histopathology. Arch. Ophthalmol. 95 (1977) 1051-1058
28. Dentchev T., Hahn P., and Dunaief J.L. Strong labeling for iron and the iron-handling proteins ferritin and ferroportin in the photoreceptor layer in age-related macular degeneration. Arch. Ophthalmol. 123 (2005) 1745-1746
29. Donovan A., Brownlie A., Zhou Y., Shepard J., Pratt S.J., Moynihan J., Paw B.H., Drejer A., Barut B., Zapata A., Law T.C., Brugnara C., Lux S.E., Pinkus G.S., Pinkus J.L., Kingsley P.D., Palis J., Fleming M.D., Andrews N.C., and Zon L.I. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403 (2000) 776-781
30. Donovan A., Lima C.A., Pinkus J.L., Pinkus G.S., Zon L.I., Robine S., and Andrews N.C. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 1 (2005) 191-200
31. Drayer B., Burger P., Hurwitz B., Dawson D., and Cain J. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content?. Am. J. Roentgenol. (AJR) 149 (1987) 357-363
32. Dunaief J.L. Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan Lecture. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4660-4664
33. Dunaief J.L., Richa C., Franks E.P., Schultze R.L., Aleman T.S., Schenck J.F., Zimmerman E.A., and Brooks D.G. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology 112 (2005) 1062-1065
34. Farkas R.H., Chowers I., Hackam A.S., Kageyama M., Nickells R.W., Otteson D.C., Duh E.J., Wang C., Valenta D.F., Gunatilaka T.L., Pease M.E., Quigley H.A., and Zack D.J. Increased expression of iron-regulating genes in monkey and human glaucoma. Invest. Ophthalmol. Vis. Sci. 45 (2004) 1410-1417
35. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., Dormishian F., Domingo Jr. R., Ellis M.C., Fullan A., Hinton L.M., Jones N.L., Kimmel B.E., Kronmal G.S., Lauer P., Lee V.K., Loeb D.B., Mapa F.A., McClelland E., Meyer N.C., Mintier G.A., Moeller N., Moore T., Morikang E., Prass C.E., Quintana L., Starnes S.M., Schatzman R.C., Brunke K.J., Drayna D.T., Risch N.J., Bacon B.R., and Wolff R.K. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13 (1996) 399-408
36. Feder J.N., Penny D.M., Irrinki A., Lee V.K., Lebron J.A., Watson N., Tsuchihashi Z., Sigal E., Bjorkman P.J., and Schatzman R.C. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc. Natl. Acad. Sci. USA 95 (1998) 1472-1477
37. Galanello R., Piga A., Alberti D., Rouan M.C., Bigler H., and Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J. Clin. Pharmacol. 43 (2003) 565-572
38. Gerhardinger C., Costa M.B., Coulombe M.C., Toth I., Hoehn T., and Grosu P. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Invest. Ophthalmol. Vis. Sci. 46 (2005) 349-357
39. Gillies A., and Lahav M. Absorption of retinal and subretinal hemorrhages. Ann. Ophthalmol. 15 (1983) 1068-1074
40. Glatt H., and Machemer R. Experimental subretinal hemorrhage in rabbits. Am. J. Ophthalmol. 94 (1982) 762-773
41. Goralska M., Holley B.L., and McGahan M.C. Overexpression of H- and L-ferritin subunits in lens epithelial cells: Fe metabolism and cellular response to UVB irradiation. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1721-1727
42. Gunshin H., Mackenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., and Hediger M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388 (1997) 482-488
43. Guo B., Phillips J.D., Yu Y., and Leibold E.A. Iron regulates the intracellular degradation of iron regulatory protein 2 by the proteasome. J. Biol. Chem. 270 (1995) 21645-21651
44. Hahn P., Milam A.H., and Dunaief J.L. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch's membrane. Arch. Ophthalmol. 121 (2003) 1099-1105
45. Hahn P., Dentchev T., Qian Y., Rouault T., Harris Z.L., and Dunaief J.L. Immunolocalization and regulation of iron handling proteins ferritin and ferroportin in the retina. Mol. Vis. 10 (2004) 598-607
46. Hahn P., Qian Y., Dentchev T., Chen L., Beard J., Harris Z.L., and Dunaief J.L. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc. Natl. Acad. Sci. USA 101 (2004) 13850-13855
47. Hahn P., Ying G.S., Beard J., and Dunaief J.L. Iron levels in human retina: sex difference and increase with age. Neuroreport 17 (2006) 1803-1806
48. Haimovici R., D'Amico D.J., Gragoudas E.S., and Sokol S. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 109 (2002) 164-171
49. Halliwell B., and Gutteridge J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219 (1984) 1-14
50. Harned J., Fleisher L.N., and McGahan M.C. Lens epithelial cells synthesize and secrete ceruloplasmin: effects of ceruloplasmin and transferrin on iron efflux and intracellular iron dynamics. Exp. Eye Res. 83 (2006) 721-727
51. Harris Z.L., Takahashi Y., Miyajima H., Serizawa M., MacGillivray R.T., and Gitlin J.D. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. USA 92 (1995) 2539-2543
52. Harris Z.L., Durley A.P., Man T.K., and Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc. Natl. Acad. Sci. USA 96 (1999) 10812-10817
53. Hawkins K.N. Contribution of plasma proteins to the vitreous of the rat. Curr. Eye Res. 5 (1986) 655-663
54. Hentze M.W., and Kuhn L.C. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA 93 (1996) 8175-8182
55. Hershko C.M., Link G.M., Konijn A.M., and Cabantchik Z.I. Iron chelation therapy. Curr. Hematol. Rep. 4 (2005) 110-116
56. Hunt R.C., and Davis A.A. Release of iron by human retinal pigment epithelial cells. J. Cell. Physiol. 152 (1992) 102-110
57. Hunt R.C., Dewey A., and Davis A.A. Transferrin receptors on the surfaces of retinal pigment epithelial cells are associated with the cytoskeleton. J. Cell Sci. 92 Part 4 (1989) 655-666
58. Hunt R.C., Hunt D.M., Gaur N., and Smith A. Hemopexin in the human retina: protection of the retina against heme-mediated toxicity. J. Cell Physiol. 168 (1996) 71-80
59. Ito T., Nakano M., Yamamoto Y., Hiramitsu T., and Mizuno Y. Hemoglobin-induced lipid peroxidation in the retina: a possible mechanism for macular degeneration. Arch. Biochem. Biophys. 316 (1995) 864-872
60. Iwai K., Drake S.K., Wehr N.B., Weissman A.M., LaVaute T., Minato N., Klausner R.D., Levine R.L., and Rouault T.A. Iron-dependent oxidation, ubiquitination, and degradation of iron regulatory protein 2: implications for degradation of oxidized proteins. Proc. Natl. Acad. Sci. USA 95 (1998) 4924-4928
61. Jeong S.Y., and David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 278 (2003) 27144-27148
62. Kalinowski D.S., and Richardson D.R. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57 (2005) 547-583
63. Klein R., Wang Q., Klein B.E., Moss S.E., and Meuer S.M. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest. Ophthalmol. Vis. Sci. 36 (1995) 182-191
64. Klimtova I., Simunek T., Mazurova Y., Kaplanova J., Sterba M., Hrdina R., Gersl V., Adamcova M., and Ponka P. A study of potential toxic effects after repeated 10-week administration of a new iron chelator-salicylaldehyde isonicotinoyl hydrazone (SIH) to rabbits. Acta Med. (Hradec Kralove) 46 (2003) 163-170
65. Knave B. Electroretinography in eyes with retained intraocular metallic foreign bodies. Acta Ophthalmol. 100 Suppl. (1969) 4-63
66. Knutson M.D., Oukka M., Koss L.M., Aydemir F., and Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc. Natl. Acad. Sci. USA 102 (2005) 1324-1328
67. Koeppen A.H., and Dickson A.C. Iron in the Hallervorden-Spatz syndrome. Pediatr. Neurol. 25 (2001) 148-155
68. Krause A., Neitz S., Magert H.J., Schulz A., Forssmann W.G., Schulz-Knappe P., and Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett. 480 (2000) 147-150
69. Kuo Y.M., Duncan J.L., Westaway S.K., Yang H., Nune G., Xu E.Y., Hayflick S.J., and Gitschier J. Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum. Mol. Genet. 14 (2005) 49-57
70. Laicine E.M., and Haddad A. Transferrin, one of the major vitreous proteins, is produced within the eye. Exp. Eye Res. 59 (1994) 441-445
71. Lee P., Mohammed N., Marshall L., Abeysinghe R.D., Hider R.C., Porter J.B., and Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab. Dispos. 21 (1993) 640-644
72. Leibowitz H.M., Krueger D.E., Maunder L.R., Milton R.C., Kini M.M., Kahn H.A., Nickerson R.J., Pool J., Colton T.L., Ganley J.P., Loewenstein J.I., and Dawber T.R. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv. Ophthalmol. 24 (1980) 335-610
73. Levi S., Santambrogio P., Cozzi A., Rovida E., Corsi B., Tamborini E., Spada S., Albertini A., and Arosio P. The role of the L-chain in ferritin iron incorporation. Studies of homo and heteropolymers. J. Mol. Biol. 238 (1994) 649-654
74. Levi S., Corsi B., Bosisio M., Invernizzi R., Volz A., Sanford D., Arosio P., and Drysdale J. A human mitochondrial ferritin encoded by an intronless gene. J. Biol. Chem. 276 (2001) 24437-24440
75. Levin L.A., and Geszvain K.M. Expression of ceruloplasmin in the retina: induction after optic nerve crush. Invest. Ophthalmol. Vis. Sci. 39 (1998) 157-163
76. LeVine S.M., and Macklin W.B. Iron-enriched oligodendrocytes: a reexamination of their spatial distribution. J. Neurosci. Res. 26 (1990) 508-512
77. Li D., Ma W., Sun F., Pavlidis P., and Spector A. Cluster analysis of genes with significant change in expression in cells conditioned to survive TBOOH. Exp. Eye Res. 78 (2004) 301-308
78. Linsenmayer T.F., Cai C.X., Millholland J.M., Beazley K.E., and Fitch J.M. Nuclear ferritin in corneal epithelial cells: tissue-specific nuclear transport and protection from UV-damage. Prog. Retin. Eye Res. 24 (2005) 139-159
79. Liu Z.D., and Hider R.C. Design of clinically useful iron(III)-selective chelators. Med. Res. Rev. 22 (2002) 26-64
80. Luckenbach M.W., Green W.R., Miller N.R., Moser H.W., Clark A.W., and Tennekoon G. Ocular clinicopathologic correlation of Hallervorden-Spatz syndrome with acanthocytosis and pigmentary retinopathy. Am. J. Ophthalmol. 95 (1983) 369-382
81. Martin P.M., Gnana-Prakasam J.P., Roon P., Smith R.G., Smith S.B., and Ganapathy V. Expression and polarized localization of the hemochromatosis gene product HFE in retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4238-4244
82. Masciulli L., Anderson D.R., and Charles S. Experimental ocular siderosis in the squirrel monkey. Am. J. Ophthalmol. 74 (1972) 638-661
83. Massie H.R., Aiello V.R., and Williams T.R. Iron accumulation during development and ageing of Drosophila. Mech. Ageing Dev. 29 (1985) 215-220
84. Massie H.R., Aiello V.R., and Williams T.R. Inhibition of iron absorption prolongs the life span of Drosophila. Mech. Ageing Dev. 67 (1993) 227-237
85. Maxton D.G., Bjarnason I., Reynolds A.P., Catt S.D., Peters T.J., and Menzies I.S. Lactulose, 51Cr-labelled ethylenediaminetetra-acetate, l-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin. Sci. (London) 71 (1986) 71-80
86. McGahan M.C., and Fleisher L.N. Antioxidant activity of aqueous and vitreous humor from the inflamed rabbit eye. Curr. Eye Res. 5 (1986) 641-645
87. McGahan M.C., Harned J., Grimes A.M., and Fleisher L.N. Regulation of ferritin levels in cultured lens epithelial cells. Exp. Eye Res. 59 (1994) 551-555
88. McGahan M.C., Harned J., Goralska M., Sherry B., and Fleisher L.N. Transferrin secretion by lens epithelial cells in culture. Exp. Eye Res. 60 (1995) 667-673
89. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., and Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 5 (2000) 299-309
90. Miyahara T., Kikuchi T., Akimoto M., Kurokawa T., Shibuki H., and Yoshimura N. Gene microarray analysis of experimental glaucomatous retina from cynomologous monkey. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4347-4356
91. Moiseyev G., Chen Y., Takahashi Y., Wu B.X., and Ma J.X. RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc. Natl. Acad. Sci. USA 102 (2005) 12413-12418
92. Morris C.M., Candy J.M., Oakley A.E., Bloxham C.A., and Edwardson J.A. Histochemical distribution of non-haem iron in the human brain. Acta Anat. (Basel) 144 (1992) 235-257
93. Nemeth E., and Ganz T. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr. 26 (2006) 323-342
94. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., and Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
95. Newell F.W., Johnson II R.O., and Huttenlocher P.R. Pigmentary degeneration of the retina in the Hallervorden-Spatz syndrome. Am. J. Ophthalmol. 88 (1979) 467-471
96. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., and Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc. Natl. Acad. Sci. USA 98 (2001) 8780-8785
97. Nicolas G., Bennoun M., Porteu A., Mativet S., Beaumont C., Grandchamp B., Sirito M., Sawadogo M., Kahn A., and Vaulont S. Severe iron deficiency anemia in transgenic mice expressing liver hepcidin. Proc. Natl. Acad. Sci. USA 99 (2002) 4596-4601
98. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., Beaumont C., Kahn A., and Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110 (2002) 1037-1044
99. Olivieri N.F., Buncic J.R., Chew E., Gallant T., Harrison R.V., Keenan N., Logan W., Mitchell D., Ricci G., Skarf B., et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N. Engl. J. Med. 314 (1986) 869-873
100. Osaki S. Kinetic studies of ferrous ion oxidation with crystalline human ferroxidase (ceruloplasmin). J. Biol. Chem. 241 (1966) 5053-5059
101. Osaki S., Johnson D.A., and Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J. Biol. Chem. 241 (1966) 2746-2751
102. Park C.H., Valore E.V., Waring A.J., and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 276 (2001) 7806-7810
103. Patel B.N., and David S. A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J. Biol. Chem. 272 (1997) 20185-20190
104. Patel B.N., Dunn R.J., and David S. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J. Biol. Chem. 275 (2000) 4305-4310
105. Patel B.N., Dunn R.J., Jeong S.Y., Zhu Q., Julien J.P., and David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J. Neurosci. 22 (2002) 6578-6586
106. Pietrangelo A. The ferroportin disease. Blood Cells Mol. Dis. 32 (2004) 131-138
107. Pietrangelo A. Non-HFE hemochromatosis. Semin. Liver Dis. 25 (2005) 450-460
108. Pietrangelo A. Hereditary hemochromatosis. Biochim. Biophys. Acta 1763 (2006) 700-710
109. Piga A., Galanello R., Cappellini M.D., Forni G., Opitz H., Ford J., Sechaud R., Mueller C., Donato C., and Alberti D. Phase II study of oral chelator ICL670 in thalassemia patients with transfusional iron overload: efficacy, safety pharmacokinetics and pharmacokinetics and pharmacodynamics after 6 months of therapy [abstract]. Blood 100 (2002) 5a
110. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., and Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J. Biol. Chem. 276 (2001) 7811-7819
111. Pippard M.J. Desferrioxamine-induced iron excretion in humans. Baillieres Clin. Haematol. 2 (1989) 323-343
112. Porter N., Downes S.M., Fratter C., Anslow P., and Nemeth A.H. Catastrophic visual loss in a patient with Friedreich ataxia. Arch. Ophthalmol. 125 (2007) 273-274
113. Poss K.D., and Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc. Natl. Acad. Sci. USA 94 (1997) 10919-10924
114. Richardson D.R. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann. NY Acad. Sci. 1012 (2004) 326-341
115. Richardson D.R., Wis Vitolo L.M., Hefter G.T., May P.M., Clare B.W., Webb J., and Wilairat P. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part I. Ionization characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta 170 (1990) 165-170
116. Rogers B.S., Symons R.C., Komeima K., Shen J., Xiao W., Swaim M.E., Gong Y.Y., Kachi S., and Campochiaro P.A. Differential sensitivity of cones to iron-mediated oxidative damage. Invest. Ophthalmol. Vis. Sci. 48 (2007) 438-445
117. Roncagliolo M., Garrido M., Walter T., Peirano P., and Lozoff B. Evidence of altered central nervous system development in infants with iron deficiency anemia at 6 mo: delayed maturation of auditory brainstem responses. Am. J. Clin. Nutr. 68 (1998) 683-690
118. Roth A.M., and Foos R.Y. Ocular pathologic changes in primary hemochromatosis. Arch. Ophthalmol. 87 (1972) 507-514
119. Rouault T.A. Post-transcriptional regulation of human iron metabolism by iron regulatory proteins. Blood Cells Mol. Dis. 29 (2002) 309-314
120. Rouault T.A., and Cooperman S. Brain iron metabolism. Semin. Pediatr. Neurol. 13 (2006) 142-148
121. Rouault T.A., and Klausner R.D. Iron-sulfur clusters as biosensors of oxidants and iron. Trends Biochem. Sci. 21 (1996) 174-177
122. Sarkar J., Seshadri V., Tripoulas N.A., Ketterer M.E., and Fox P.L. Role of ceruloplasmin in macrophage iron efflux during hypoxia. J. Biol. Chem. 278 (2003) 44018-44024
123. Schichi H. Microsomal electron transport system of bovine retinal pigment epithelium. Exp. Eye Res. 8 (1969) 60-68
124. Shaikh S., and Blumenkranz M.S. Fluorescein angiographic findings in ocular siderosis. Am. J. Ophthalmol. 131 (2001) 136-138
125. Simunek T., Boer C., Bouwman R.A., Vlasblom R., Versteilen A.M., Sterba M., Gersl V., Hrdina R., Ponka P., de Lange J.J., Paulus W.J., and Musters R.J. SIH-a novel lipophilic iron chelator-protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death. J. Mol. Cell Cardiol. 39 (2005) 345-354
126. Sipe D.M., and Murphy R.F. Binding to cellular receptors results in increased iron release from transferrin at mildly acidic pH. J. Biol. Chem. 266 (1991) 8002-8007
127. Smith M.A., Harris P.L., Sayre L.M., and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94 (1997) 9866-9868
128. Sneed S.R. Ocular siderosis. Arch. Ophthalmol. 106 (1988) 997
129. Sullivan J.L. Is stored iron safe?. J. Lab. Clin. Med. 144 (2004) 280-284
130. Talamo J.H., Topping T.M., Maumenee A.E., and Green W.R. Ultrastructural studies of cornea, iris and lens in a case of siderosis bulbi. Ophthalmology 92 (1985) 1675-1680
131. Tenenbein M., Kowalski S., Sienko A., Bowden D.H., and Adamson I.Y. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 339 (1992) 699-701
132. Trese M.T. Visual results and prognostic factors for vision following surgery for stage V retinopathy of prematurity. Ophthalmology 93 (1986) 574-579
133. Tripathi R.C., Millard C.B., Tripathi B.J., Chailertborisuth N.S., Neely K.A., and Ernest J.T. Aqueous humor of cat contains fibroblast growth factor and transferrin similar to those in man. Exp. Eye Res. 50 (1990) 109-112
134. Vanorden H.E., and Hagemann T.M. Deferasirox-an oral agent for chronic iron overload. Ann. Pharmacother. 40 (2006) 1110-1117
135. Vogi W., Nolte R., and Brunahl D. Binding of iron to the 5th component of human complement directs oxygen radical-mediated conversion to specific sites and causes nonenzymic activation. Complement Inflamm. 8 (1991) 313-319
136. Vulpe C.D., Kuo Y.M., Murphy T.L., Cowley L., Askwith C., Libina N., Gitschier J., and Anderson G.J. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the Sla mouse. Nat. Genet. 21 (1999) 195-199
137. Wigglesworth J.M., and Baum H. Iron-dependent enzymes in the brain. In: Youdim M.B.H. (Ed). Topics in Neurochemistry and Neuropharmacology (1988), Taylor & Francis, London 25-66
138. Yamaguchi K., Takahashi S., Kawanami T., Kato T., and Sasaki H. Retinal degeneration in hereditary ceruloplasmin deficiency. Ophthalmologica 212 (1998) 11-14
139. Yang F., Wang X., Haile D.J., Piantadosi C.A., and Ghio A.J. Iron increases expression of iron-export protein MTP1 in lung cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 283 (2002) L932-L939
140. Yau K.W., and Baylor D.A. Cyclic GMP-activated conductance of retinal photoreceptor cells. Annu. Rev. Neurosci. 12 (1989) 289-327
141. Yefimova M.G., Jeanny J.C., Guillonneau X., Keller N., Nguyen-Legros J., Sergeant C., Guillou F., and Courtois Y. Iron, ferritin, transferrin, and transferrin receptor in the adult rat retina. Invest. Ophthalmol. Vis. Sci. 41 (2000) 2343-2351
142. Yefimova M.G., Jeanny J.C., Keller N., Sergeant C., Guillonneau X., Beaumont C., and Courtois Y. Impaired retinal iron homeostasis associated with defective phagocytosis in Royal College of Surgeons rats. Invest. Ophthalmol. Vis. Sci. 43 (2002) 537-545
143. Youdim M.B.H. Neuropharmacological and neurobiochemical aspects of iron deficiency. In: Dobbing J. (Ed). Brain, Behavior, and Iron in the Infant Diet (1990), Springer, London 83-106
144. Youssef T.A., Trese M.T., Hartzer M., Mahgoub M., Raza H., Azrak M., and Allredge C. Deferoxamine reduced retinal toxicity from subretinal blood. Invest. Ophthalmol. 43 (2002) (E-abstract)
145. Yu T.C., and Okamura R. Quantitative study of characteristic aqueous humor transferrin, serum transferrin and desialized serum transferrin in aqueous humor. Jpn. J. Ophthalmol. 32 (1988) 268-274
146. Zarbin M.A. Current concepts in the pathogenesis of age-related macular degeneration. Arch. Ophthalmol. 122 (2004) 598-614
147. Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., Youdim M.B., and Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 13 (2005) 773-783
148. Zhou B., Westaway S.K., Levinson B., Johnson M.A., Gitschier J., and Hayflick S.J. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 28 (2001) 345-349